| 1. |
Influence of drug companies on physicians |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1462,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
UK NICE releases imatinib guidance for GISTs ... |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1462,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Effect of Vioxx withdrawal on COX-2 inhibitor prescribing |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1462,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
New selective screening policy for chlamydia warranted |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1462,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
QOL news from the 14th Annual Congress of the ERS |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1462,
2004,
Page 6-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Employers stand to gain from bupropion for smoking cessation |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1462,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
VB 4845 [Proxinium]*has promising activity in advanced, recurrent head and neck cancer, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1462,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
DCEP an alternative to standard regimen in myeloma |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1462,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Transplacental dexamethasone improves outcomes in fetal CAVB |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1462,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Montelukast an alternative to inhaled corticosteroids in children |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1462,
2004,
Page 11-12
S Sullivan,
Preview
|
|
摘要:
The leukotriene receptor antagonist montelukast [Singulair] is effective in controlling mild asthma in children, according to studies presented at the 14th Annual Congress of the European Respiratory Society (ERS) [Glasgow, UK; September 2004]. The MOSAIC study found montelukast to be as effective as fluticasone propionate in increasing the number of asthma rescue-free days in children aged 6−14 years with mild asthma, but with less effect on growth rates. Another study, involving children aged 2−5 years, showed that montelukast significantly improved daytime and night-time asthma symptom scores, compared with placebo. Furthermore, montelukast was shown to have similar efficacy to beclometasone in patients with moderate asthma.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
